Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases

Area of Science:

• Oncolytic virotherapy
• Cancer research
• Virology

Background:

• Oncolytic viruses are emerging as promising cancer therapeutics.
• Targeting solid tumors and metastases with oncolytic viruses remains challenging.
• Developing effective delivery systems is crucial for oncolytic virus efficacy.

Purpose of the Study:

• To evaluate a cell-based carrier system for delivering oncolytic parvoviruses.
• To assess the efficacy of this system in treating lung metastases.
• To compare the carrier system with direct virus administration.

Main Methods:

• Organotropic cell-based carriers infected with parvovirus H-1.
• Carrier cells inactivated by gamma-irradiation.
• Administration of infected carriers to rats with Morris hepatoma lung metastases.
• Assessment of virus expression, therapeutic effect, and antibody generation.

Main Results:

• Inactivated carrier cells sustained oncolytic parvovirus expression in lung metastases for 6 days.
• The carrier cell system demonstrated improved therapeutic efficacy in suppressing metastases.
• Reduced virus spread to peripheral organs and lower generation of virus-neutralizing antibodies were observed.
• Parvoviruses released from carriers effectively lysed cocultured neoplastic cells.

Conclusions:

• Cell-based carrier systems are suitable for delivering oncolytic parvoviruses to target tissues, particularly metastases.
• This strategy offers advantages over direct virus injection, including enhanced therapeutic effects and reduced immunogenicity.
• The findings support the use of carrier cells for localized delivery of oncolytic viruses in cancer treatment.